XGN Valuation
Exagen Inc
$
7.440
- Overview
- Forecast
- Valuation
- Earnings
XGN Relative Valuation
XGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XGN is overvalued; if below, it's undervalued.
Historical Valuation
Exagen Inc (XGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.32 is considered Undervalued compared with the five-year average of -4.59. The fair price of Exagen Inc (XGN) is between 28.28 to 36.43 according to relative valuation methord. Compared to the current price of 7.44 USD , Exagen Inc is Undervalued By 73.7%.
Relative Value
Fair Zone
28.28-36.43
Current Price：7.44
73.7%
Undervalued
-14.80
PE
1Y
3Y
5Y
Trailing
Forward
-54.90
EV/EBITDA
Exagen Inc. (XGN) has a current EV/EBITDA of -54.90. The 5-year average EV/EBITDA is -6.54. The thresholds are as follows: Strongly Undervalued below -32.12, Undervalued between -32.12 and -19.33, Fairly Valued between 6.25 and -19.33, Overvalued between 6.25 and 19.04, and Strongly Overvalued above 19.04. The current Forward EV/EBITDA of -54.90 falls within the Strongly Undervalued range.
-19.65
EV/EBIT
Exagen Inc. (XGN) has a current EV/EBIT of -19.65. The 5-year average EV/EBIT is -3.91. The thresholds are as follows: Strongly Undervalued below -12.53, Undervalued between -12.53 and -8.22, Fairly Valued between 0.40 and -8.22, Overvalued between 0.40 and 4.72, and Strongly Overvalued above 4.72. The current Forward EV/EBIT of -19.65 falls within the Strongly Undervalued range.
2.32
PS
Exagen Inc. (XGN) has a current PS of 2.32. The 5-year average PS is 2.14. The thresholds are as follows: Strongly Undervalued below -1.03, Undervalued between -1.03 and 0.55, Fairly Valued between 3.73 and 0.55, Overvalued between 3.73 and 5.31, and Strongly Overvalued above 5.31. The current Forward PS of 2.32 falls within the Historic Trend Line -Fairly Valued range.
-21.72
P/OCF
Exagen Inc. (XGN) has a current P/OCF of -21.72. The 5-year average P/OCF is -5.82. The thresholds are as follows: Strongly Undervalued below -18.76, Undervalued between -18.76 and -12.29, Fairly Valued between 0.65 and -12.29, Overvalued between 0.65 and 7.12, and Strongly Overvalued above 7.12. The current Forward P/OCF of -21.72 falls within the Strongly Undervalued range.
-27.25
P/FCF
Exagen Inc. (XGN) has a current P/FCF of -27.25. The 5-year average P/FCF is -5.98. The thresholds are as follows: Strongly Undervalued below -17.37, Undervalued between -17.37 and -11.67, Fairly Valued between -0.28 and -11.67, Overvalued between -0.28 and 5.42, and Strongly Overvalued above 5.42. The current Forward P/FCF of -27.25 falls within the Strongly Undervalued range.
Exagen Inc (XGN) has a current Price-to-Book (P/B) ratio of 20.38. Compared to its 3-year average P/B ratio of 3.57 , the current P/B ratio is approximately 470.40% higher. Relative to its 5-year average P/B ratio of 3.25, the current P/B ratio is about 527.12% higher. Exagen Inc (XGN) has a Forward Free Cash Flow (FCF) yield of approximately -9.79%. Compared to its 3-year average FCF yield of -52.03%, the current FCF yield is approximately -81.18% lower. Relative to its 5-year average FCF yield of -36.07% , the current FCF yield is about -72.86% lower.
20.38
P/B
Median3y
3.57
Median5y
3.25
-9.79
FCF Yield
Median3y
-52.03
Median5y
-36.07
Competitors Valuation Multiple
The average P/S ratio for XGN's competitors is 36.38, providing a benchmark for relative valuation. Exagen Inc Corp (XGN) exhibits a P/S ratio of 2.32, which is -93.63% above the industry average. Given its robust revenue growth of 7.51%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of XGN increased by 272.82% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.38 to -8.61.
The secondary factor is the Revenue Growth, contributed 7.51%to the performance.
Overall, the performance of XGN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Exagen Inc (XGN) currently overvalued or undervalued?
Exagen Inc (XGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.32 is considered Undervalued compared with the five-year average of -4.59. The fair price of Exagen Inc (XGN) is between 28.28 to 36.43 according to relative valuation methord. Compared to the current price of 7.44 USD , Exagen Inc is Undervalued By 73.70% .
What is Exagen Inc (XGN) fair value?
How does XGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Exagen Inc (XGN) as of Jul 28 2025?
What is the current FCF Yield for Exagen Inc (XGN) as of Jul 28 2025?
What is the current Forward P/E ratio for Exagen Inc (XGN) as of Jul 28 2025?